|
|
|
The Iverson Warfarin Dosing Panel XP identifies a wide range of genetic variants in two enzymes which play key roles in determining an individual’s maintenance dose of the blood thinner warfarin. Once identified, these genetic markers may inform initial dosing estimates and increase the safety and efficacy of warfarin therapy.
The Iverson Warfarin Dosing Panel has significant advantages over the competition. Our test identifies seven different variations of the CYP2C9 gene and nine different variations of the VKORC1 gene.
Warfarin Dosing- More than 2,000,000 new warfarin prescriptions are being written every year in the United States alone
- There is a 10-fold inter-patient variability in the dosing required to attain a therapeutic response1
- The anticoagulant warfarin has a narrow therapeutic window, with too little leaving patients at risk for thrombosis and too much leading to the potential for hemorrhage
- Major bleeding events occur in 50% of patients during the first 90 days of warfarin treatment1
- Trial and error predominates as the method of dosing warfarin: virtually the only contemporary drug prescribed using trial and error methodology2
- Together, two enzymes (VKORC1 and CYP2C9) account for up to 50% of the individual variability in warfarin response3
- The Iverson Warfarin Dosing Panel includes these additional variants while most other panels do not.
Terms (*)
VKORC1: vitamin K epoxide reductase complex subunit-1. VKORC1 recycles Vitamin K which is needed to make functional clotting factors. VKORC1 action is blocked by warfarin and its destruction is the intended target of warfarin therapy.
CYP2C9: The cytochrome P450 enzyme CYP2C9 metabolizes warfarin. The variants (*2, *3, *4, *5, *6, *11) differ from the wild type (*1) by a single amino acid substitution. The variants are associated with impaired metabolism of S-warfarin and these patients are potentially at risk for warfarin overdosing.
INR: International Normalized Ratio. The ratio of prothrombin time compared to normal controls (standardized to account the amount of reagents used). The target INR for most indications is usually between 2.0 and 3.0.
References
- Fanikos, John, et. al. Major bleeding complications in a specialized anticoagulation service. American Journal of Cardiology. 2005; 96: 595-98.
- Bodin, L, et all. “Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity” Blood. 2005 Jul 1;106(1):135-40. Epub 2005 Mar 24.
|
|
|
|
|
|
|
|
|
Our Expanded Panel Covers Ethnicities
Other tests do offer this capability.
Rapid Turnaround Time
2-day turnaround available now from anywhere in the country
|
|
|
